Literature DB >> 29733099

Long-term opioid users with chronic noncancer pain: Assessment of opioid abuse risk and relationship with healthcare resource use.

Anna D Coutinho1, Kavita Gandhi2, Rupali M Fuldeore1, Pamela B Landsman-Blumberg1, Sanjay Gandhi3.   

Abstract

OBJECTIVE: Identify opioid abuse risk factors among chronic noncancer pain (CNCP) patients receiving long-term opioid therapy and assess healthcare resource use (HRU) among patients at elevated abuse risk.
DESIGN: Data were obtained from an integrated administrative claims database. Classification and Regression Tree (CART) analysis identified risk factors potentially predictive of opioid abuse, which were used to classify the overall population into cohorts defined by levels of abuse risk. Multivariable logistic regression compared HRU across risk cohorts.
SETTING: Retrospective cohort study. PATIENTS, PARTICIPANTS: 21,072 patients aged ≥18 years diagnosed with ≥1 of 5 types of CNCP and a prescription for Schedule II or III/IV opioid medication used long-term (≥90 days). MAIN OUTCOME MEASURES: (1) Opioid abuse risk factors; (2) HRU differences between risk cohorts.
RESULTS: CART analysis identified four groups at elevated opioid abuse risk defined by three factors (age, daily opioid dose, and total days' supply of opioids); sensitivity: 70.3 percent, specificity: 74.1 percent, and positive predictive value: 5.6 percent. The analysis results were used to classify patients into low-risk (72.5 percent), at-risk (25.4 percent), and opioid-abuser (2.2 percent) cohorts. In multivariable analysis, emergency department (ED) use was higher among at-risk vs low-risk patients (odds ratio [OR]: 1.14; p<0.05); hospitalization and ED visits were higher for opioid-abusers vs low-risk patients (OR: 2.33 and 2.14, respectively; p<0.05).
CONCLUSIONS: This study identifies a subpopulation of CNCP patients at risk of opioid abuse. However, limited sensitivity and specificity of criteria defining this subpopulation reinforce the importance of physician discretion in patient-level treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29733099     DOI: 10.5055/jom.2018.0440

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  5 in total

1.  Opioid Prescribing Among Adults With Disabilities in the United States After the 2014 Federal Hydrocodone Rescheduling Regulation.

Authors:  Victor Liaw; Yong-Fang Kuo; Mukaila A Raji; Jacques Baillargeon
Journal:  Public Health Rep       Date:  2020-01       Impact factor: 2.792

2.  Pain rates in general population for the period 1991-2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis.

Authors:  Davide Guido; Matilde Leonardi; Blanca Mellor-Marsá; Maria V Moneta; Albert Sanchez-Niubo; Stefanos Tyrovolas; Iago Giné-Vázquez; Josep M Haro; Somnath Chatterji; Martin Bobak; Jose L Ayuso-Mateos; Holger Arndt; Ilona Koupil; Jerome Bickenbach; Seppo Koskinen; Beata Tobiasz-Adamczyk; Demosthenes Panagiotakos; Alberto Raggi
Journal:  J Headache Pain       Date:  2020-05-13       Impact factor: 7.277

3.  Effects of pulsed low-frequency magnetic field therapy on pain intensity in patients with musculoskeletal chronic low back pain: study protocol for a randomised double-blind placebo-controlled trial.

Authors:  Fuad A Abdulla; Saad Alsaadi; Mir Sadat-Ali; Fahd Alkhamis; Hani Alkawaja; Serigne Lo
Journal:  BMJ Open       Date:  2019-06-09       Impact factor: 2.692

4.  Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events.

Authors:  Siyana Kurteva; Michal Abrahamowicz; Tara Gomes; Robyn Tamblyn
Journal:  JAMA Netw Open       Date:  2021-05-03

5.  Development of an Emergency Department-Based Intervention to Expand Access to Medications for Opioid Use Disorder in a Medicaid Nonexpansion Setting: Protocol for Engagement and Community Collaboration.

Authors:  Lauren A Walter; Li Li; Erik P Hess; Joel B Rodgers; Jennifer J Hess; Rachel M Skains; Matthew C Delaney; James Booth
Journal:  JMIR Res Protoc       Date:  2021-04-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.